News & Updates
The latest news and advances from the world's most exciting life science cluster.
Sonoma Biosciences, which splits operations between South San Francisco and Seattle, received $40 million in financing to develop cell therapies for autoimmune diseases. Traditionally used
Silverback Therapeutics announced that it received $85 million in Series C funding, following closely on the heels of a $78.5 million funding round in March
Pharmaceutical company Merck and Bothell, Washington-based Seattle Genetics have formed a partnership to advance two key cancer therapies. The first involves expanding Tukysa, the drug
Gilead Sciences announced it has acquired Immunomedics, a developer of antibody-drug conjugate (ADC) technology used to treat cancers. Immunomedics gained attention with the success of
Following a blockbuster deal with pharmaceutical company Merck, Seattle Genetics released plans to build a $300 million manufacturing facility, two to three times the size
Washington was named the best state to work in during the COVID-19 pandemic, according to a report released by Oxfam America. The study looked at